Rain Oncology Management
Management criteria checks 1/4
Rain Oncology's CEO is Avanish Vellanki, appointed in Apr 2017, has a tenure of 6.75 years. total yearly compensation is $2.19M, comprised of 27% salary and 73% bonuses, including company stock and options. directly owns 7.01% of the company’s shares, worth $3.09M. The average tenure of the management team and the board of directors is 1.9 years and 5.5 years respectively.
Key information
Avanish Vellanki
Chief executive officer
US$2.2m
Total compensation
| CEO salary percentage | 27.0% |
| CEO tenure | 6.8yrs |
| CEO ownership | 7.0% |
| Management average tenure | 1.9yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
Is Rain Oncology (NASDAQ:RAIN) In A Good Position To Invest In Growth?
Feb 23
We Think Rain Therapeutics (NASDAQ:RAIN) Needs To Drive Business Growth Carefully
Nov 08Rain Therapeutics GAAP EPS of -$0.66 in-line
Aug 04Here's Why We're Watching Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Situation
Aug 03We're Not Very Worried About Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Rate
Apr 17We Think Rain Therapeutics (NASDAQ:RAIN) Can Afford To Drive Business Growth
Dec 25We're Hopeful That Rain Therapeutics (NASDAQ:RAIN) Will Use Its Cash Wisely
Sep 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$72m |
| Jun 30 2023 | n/a | n/a | -US$83m |
| Mar 31 2023 | n/a | n/a | -US$79m |
| Dec 31 2022 | US$2m | US$590k | -US$76m |
| Sep 30 2022 | n/a | n/a | -US$71m |
| Jun 30 2022 | n/a | n/a | -US$71m |
| Mar 31 2022 | n/a | n/a | -US$62m |
| Dec 31 2021 | US$818k | US$497k | -US$51m |
| Sep 30 2021 | n/a | n/a | -US$39m |
| Jun 30 2021 | n/a | n/a | -US$31m |
| Mar 31 2021 | n/a | n/a | -US$25m |
| Dec 31 2020 | US$729k | US$394k | -US$21m |
Compensation vs Market: Avanish's total compensation ($USD2.19M) is above average for companies of similar size in the US market ($USD717.13K).
Compensation vs Earnings: Avanish's compensation has increased whilst the company is unprofitable.
CEO
Avanish Vellanki (48 yo)
6.8yrs
Tenure
US$2,190,271
Compensation
Mr. Avanish Vellanki, M.B.A., co-founded Rain Therapeutics Inc in April 2017 and has been its Chief Executive Officer and Chairman since inception. Prior to Rain, Mr. Vellanki served as Senior Vice Preside...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 6.8yrs | US$2.19m | 7.01% $ 3.1m | |
| Co-Founder | 6.8yrs | US$1.43m | 1.31% $ 577.0k | |
| Principal Financial & Accounting officer | less than a year | no data | 0.0085% $ 3.7k | |
| Director of Corporate Development & Operations | no data | no data | no data | |
| General Counsel & Chief Compliance Officer | less than a year | no data | no data | |
| Vice President of People & Culture | no data | no data | no data | |
| Senior VP & Head of Research | no data | no data | no data | |
| MD & VP of Clinical Development | 1.9yrs | no data | no data |
1.9yrs
Average Tenure
49.5yo
Average Age
Experienced Management: RAIN's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 6.8yrs | US$2.19m | 7.01% $ 3.1m | |
| Co-Founder | 6.8yrs | US$1.43m | 1.31% $ 577.0k | |
| lead Independent Director | 3.7yrs | US$117.75k | 2.76% $ 1.2m | |
| Independent Director | 3.3yrs | US$82.75k | no data | |
| Member of Scientific Advisory Board | 5.3yrs | no data | no data | |
| Independent Director | 5.8yrs | US$94.25k | 0% $ 0 | |
| Member of Scientific Advisory Board | 1.1yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.8yrs | US$83.25k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$89.25k | 0.024% $ 10.6k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.8yrs | US$80.25k | 0% $ 0 |
5.5yrs
Average Tenure
51yo
Average Age
Experienced Board: RAIN's board of directors are considered experienced (5.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/26 04:47 |
| End of Day Share Price | 2024/01/26 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rain Oncology Inc. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Charles Butler | D. Boral Capital LLC. |
| Michael Schmidt | Guggenheim Securities, LLC |